[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

方法	例数	Monitor-100沉血仪		魏氏法
方法	例数	30 min模式	60 min模式	魏氏法
ESR≤20 mm/h	66	6.24±5.96	6.26±5.24	8.02±4.94
ESR 21~60 mm/h	30	27.80±11.43	31.07±10.66	37.80±11.56
ESR≥61 mm/h	9	66.89±11.66	74.00±16.07	88.22±16.32
合计	105	17.60±19.68	19.15±21.70	23.40±25.31

方法	例数	Monitor-100沉血仪		魏氏法
方法	例数	30 min模式	60 min模式	魏氏法
ESR≤20 mm/h	66	6.24±5.96	6.26±5.24	8.02±4.94
ESR 21~60 mm/h	30	27.80±11.43	31.07±10.66	37.80±11.56
ESR≥61 mm/h	9	66.89±11.66	74.00±16.07	88.22±16.32
合计	105	17.60±19.68	19.15±21.70	23.40±25.31

RichHTML

PDF (PC)

[1]	刘成玉. 临床检验基础[M].北京:人民卫生出版社,2012:39.
[2]	JOU J M,LEWIS S M,BRIGGS C,et al.ICSH review of the measurement of the erythrocyte sedimentation rate[J]. Int J Lab Hematol,2011,33(2):125-132.
[3]	叶应妩,王毓三,申子瑜. 全国临床检验操作规程[M]. 3版. 南京:东南大学出版社,2006:143-144.
[4]	熊立凡,刘成玉. 临床检验基础[M]. 4版. 北京:人民卫生出版社,2007:38-41.
[5]	郑文芝,温晓艳,李立宏,等. Precil XC-20型自动血沉仪应用评价[J]. 检验医学,2005,20(5):490-491.
[6]	FABRY T L.Mechanism of erythrocyte aggregation and sedimentation[J]. Blood,1987,70(5):1572-1576.